Summary: Retatrutide FDA Status Retatrutide is not FDA-approved and won't be for at least another year It's in Phase 3 trials (TRIUMPH program) with results expected in late 2026 FDA approval is projected for 20272028 Phase 2 data showed 24.2% weight loss , better than any approved GLP-1 medication Current access: clinical trials (free), compounded retatrutide ($200$500/mo), or research peptides ($150$500/mo) When approved, retatrutide will be the first triple-agonist obesity medication on the market References Jastreboff AM, Aronne LJ, Ahmad NN, et al
Supports Detoxification, Skin Brightening & Immunity Boost: Miduty Liposomal Glutathione helps detoxify the liver, neutralize free radicals, and strengthen immune function
Additionally, people on time-sensitive medications like levodopa should work closely with their healthcare providers to monitor their response and adjust timing if needed
It neutralizes free radicals, which are known for damaging cells and contributing to aging and various chronic health challenges
Products may carry risks, including immunogenicity or impurities
